Skip to content
Wenlo
Sign in
← Markets

Tenax Therapeutics, Inc.

ADAR1 Capital Management, LLC (10% owner) buys TENX shares

4TENXFiled Oct 21, 2026, 12:49 PM ET· Period Oct 19, 2026

About this filing

Tenax Therapeutics, Inc. (TENX) filed Form 4 (insider transaction) with the SEC on Oct 21, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider 1
ADAR1 Capital Management, LLC · 10% owner
Insider 2
Daniel Schneeberger · 10% owner
DateTransactionSharesPriceValueHeld afterOwnership
Oct 19, 2026P · purchaseFootnotes F1, F4, F5+336,528$1.51$507,013.086,860,679Indirect (See Footnote)
Oct 20, 2026P · purchaseFootnotes F2, F4, F5+254,342$1.60$405,726.367,115,021Indirect (See Footnote)
Oct 21, 2026P · purchaseFootnotes F3, F4, F5+331,979$1.66$550,686.777,447,000Indirect (See Footnote)
Footnotes
  1. F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4300 to $1.5350, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5000 to $1.6300, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6200 to $1.6900, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  5. F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

More TENX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.